Prosensa slides on drisapersen data concerns

|About: Prosensa Holding N.V. (RNA)|By:, SA News Editor

Not surprisingly, shares of Prosensa (RNA -9%) are notably weaker on the session after data from a trial of drisapersen is optically less impressive in terms of dystrophin response than Sarepta's eteplirsen data.

Some caution is warranted when interpreting the results however, as comparisons of the GSK/ RNA data to SRPT's results may be "apples to oranges," to use Baird's terminology.